Scientists from the Cancer Research UK Manchester Institute at The University of Manchester say they have been working on finding new molecules that play a role in tumor suppression.
Antibiotic R&D fell out of favor at Big Pharma companies years ago, chilling a field that only recently has shown signs of heating up with new development projects. But a transatlantic team of investigators electrified the field this week with its claims that a new antibiotic found in dirt was a potent killer of drug-resistant bacteria. And it could represent a new class of badly needed antibiotics that just might avoid the natural resistance that begins to evolve once a new antibiotic hits the market.
A team at Scripps is identifying enzymes that influence production of an inflammatory lipid molecule in the brain, offering a prime target for drug developers and insights that may also assist investigators in fields involving brain inflammation, such as multiple sclerosis, Alzheimer's, Parkinson's and ALS.
Fast on the heels of the FDA's approval of Blincyto (blinatumomab), Amgen's new leukemia fighter that uses a bispecific T cell engager system to flag cancer cells for the immune system to destroy, the Big Biotech has partnered up with MD Anderson in Texas on a new program aimed at identifying targets for this technology in myelodysplastic syndrome.
About one of every 5 cases of breast cancer are termed triple-negative. They are hard to treat and resistant to some of the therapies currently in use, and as a result patients in this subtype have a worse chance of beating the disease or delaying its progress significantly. But now a team of scientists in the U.K. says that they have identified a gene that appears to drive disease progression and might offer a good target for drug developers.
An attempt by Nabi to develop a new nicotine vaccine failed decisively in clinical studies, chilling the field for researchers who once dreamed of coming up with a better way to break a habit that can kill people through any of 8 different cancers. But now a team at Scripps Research Institute believe they've cracked the biologic code that defeated NicVAX and discovered how you could develop a vaccine that works.
Investigators at Baylor College of Medicine say that new animal research indicates that a certain type of T cell found in the immune system could be a good target for drug developers spotlighting Type 2 diabetes triggered by obesity as well as insulin resistance.
Researchers at Oregon State University have adapted a known molecule so that it sticks to cancer cells, opening up a new approach to better identifying tumors for surgical removal while providing a follow-up attack on any remaining malignant cells, helping to prevent the cancer from making a comeback.
Animal studies typically don't do much for a biotech's stock price. Findings can be hard to replicate, animal models often don't translate well to human studies and hopeful signs seen at the preclinical stage can vanish in an instant--particularly in tough fields like neurodegeneration.
CRISPR technology's potential for gene editing has helped inspire the launch of a trio of closely watched biotech startups with their sights set on some cutting-edge approaches to new therapeutics. And now a team at Johns Hopkins has done some experiments to demonstrate its promise in engineering human stem cell therapies.
A team at Children's Hospital of Philadelphia says they've debunked a common misconception about the mTORC1 pathway and come up with a new and better approach that has proved promising in an animal model of Huntington's disease.
Two prominent researchers whose work on stem cells has come under review have fired back at Harvard Medical School and Brigham & Women's Hospital in a lawsuit, blaming a coauthor for the problems that triggered one paper to be retracted and another questioned while claiming that the university mishandled its investigation into their efforts.
Stem cell investigator Haruko Obokata has resigned from Japan's RIKEN Center for Developmental Biology some months after a paper she co-authored on a new method to create pluripotent stem cells was retracted.
Dr. Jack Elias, dean of medicine and biological sciences at Brown University, has been studying the role of a protein called chitinase 3-like-1 in fibrosis and asthma for years. And now he says that new animal research indicates that this could also be a good target for cancer metastasis.
While studying the effects and causes of hepatitis C infection of the liver, a group of scientists at Aarhus University in Denmark say they discovered a key driver of the disease that could prove particularly effective in helping patients with hard-to-treat cases.
Longtime Alzheimer's researcher William Klein led a team of investigators at Northwestern University which developed a new imaging technology they say can flag the neurodegenerative disease at a very early stage of development, possibly highlighting a fresh approach for developing new therapies as well as testing them at a point when treatments may still be effective.
Johnson & Johnson and Lundbeck are throwing some scientific muscle behind a new initiative at the Wellcome Trust which enlisted researchers at 7 top academic research institutions in an effort to determine what role the immune system and inflammation play in depression and neurodegenerative diseases like Alzheimer's.
A research team says it has developed a new type of stem cell--capable of developing into any kind of tissue--that could pave the way to new cell lines that could be made more efficiently, opening up its potential in R&D.
Researchers have hit on a new approach to creating functional melanocytes, the body's pigment-producing cells. And their work could spur a fresh approach to screening and developing new drugs for melanoma as well as producing new cell-based therapies for a variety of skin diseases.